|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
JP6461118B2
(ja)
|
2013-06-21 |
2019-01-30 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規の置換された二環式化合物
|
|
SI3010503T1
(sl)
|
2013-06-21 |
2020-07-31 |
Zenith Epigenetics Ltd. |
Novi biciklični inhibitorji bromodomene
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
SG10201804471PA
(en)
|
2013-10-18 |
2018-07-30 |
Celgene Quanticel Research Inc |
Bromodomain inhibitors
|
|
EP3074389B1
(en)
*
|
2013-11-26 |
2019-08-14 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
GB201321737D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
BR112016012243A2
(pt)
*
|
2013-12-09 |
2017-08-08 |
Ucb Biopharma Sprl |
Derivados de imidazopiridina como moduladores de atividade de tnf
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
|
GB201503720D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201506660D0
(en)
*
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
JP2018527340A
(ja)
|
2015-08-11 |
2018-09-20 |
ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ |
アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
|
|
WO2017024406A1
(en)
|
2015-08-11 |
2017-02-16 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
|
KR102784592B1
(ko)
*
|
2015-08-12 |
2025-03-19 |
에피제네틱스, 인크. |
치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US10501459B2
(en)
|
2015-10-21 |
2019-12-10 |
Neomed Institute |
Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
|
|
WO2017103670A1
(en)
*
|
2015-12-14 |
2017-06-22 |
Zenith Epigenetics Lid. |
1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
|
|
US10519151B2
(en)
|
2016-01-28 |
2019-12-31 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
|
|
US10517877B2
(en)
|
2016-03-30 |
2019-12-31 |
Wisconsin Alumni Research Foundation |
Compounds and methods for modulating frataxin expression
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
GB201614940D0
(en)
*
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614939D0
(en)
*
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
EP3548034A4
(en)
*
|
2016-12-05 |
2020-07-08 |
Microbiotix, Inc. |
BROAD SPECTRUM INHIBITORS OF FILOVIRUS
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
キメラ抗原受容体の調節
|
|
US11759533B2
(en)
|
2017-03-29 |
2023-09-19 |
Wisconsin Alumni Research Foundation |
Methods and compositions for modulating gene expression
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
CN109111437B
(zh)
*
|
2017-06-22 |
2022-03-04 |
中国科学院广州生物医药与健康研究院 |
一种苯并[d]异恶唑类化合物及其制备方法和应用
|
|
CN109280046B
(zh)
*
|
2017-07-21 |
2021-02-02 |
浙江海正药业股份有限公司 |
苯并咪唑类衍生物及其制备方法及其在医药上的用途
|
|
CN110997656B
(zh)
*
|
2017-08-04 |
2023-04-14 |
百时美施贵宝公司 |
用作tlr7/8/9抑制剂的取代的吲哚化合物
|
|
US20210038602A1
(en)
*
|
2018-01-25 |
2021-02-11 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
US10442799B1
(en)
|
2018-04-07 |
2019-10-15 |
Fuqiang Ruan |
Heterocyclic compounds and uses thereof
|
|
IL302595A
(en)
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
JP2022053557A
(ja)
*
|
2019-02-08 |
2022-04-06 |
マルホ株式会社 |
ピリドン誘導体
|
|
WO2020219168A1
(en)
*
|
2019-04-24 |
2020-10-29 |
Convergene, Llc |
Small molecule bromodomain inhibitors and uses thereof
|
|
CN120623106A
(zh)
|
2019-09-30 |
2025-09-12 |
协和麒麟株式会社 |
Bet降解剂
|
|
AU2020405129A1
(en)
|
2019-12-19 |
2022-06-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|